DECOFRAC-KRH (DEvelopment of Checklist for Osteoporotic FRActure Care in Kameda Rehabilitation Hospital; a Controlled Before-and-After Trial

DECOFRAC-KRH (DEvelopment of Checklist for Osteoporotic FRActure Care in Kameda Rehabilitation Hospital; a Controlled Before-and-After Trial - DECOFRAC-KRH study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028646

Enrollment

Registered

2017-08-14

Start date

2017-08-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporotic fracture Osteoporosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Menopausal women over 50 years old with a recent history of fracture, and men over 50 years old with a recent history of fracture, who were or will be admitted to KRH.

Exclusion criteria

Exclusion criteria: 1) Patients who deny to attend this trial 2) Patients who are hospitalized due to certain diseases (fracture is not a main diagnosis)

Design outcomes

Primary

Measure	Time frame
The difference in the proportion of the patients who received "appropriate treatments" for osteoporosis between two groups. The definition of "appropriate treatments" is as follows. 1) For a patient with a history of major osteoporotic fracture (either hip or vertebral fracture). Oral bisphosphonate or denosumab in addition to vitamin D supplement . If a patient is not considered to be a good candidate for oral bisphosphonate or denosumab, the doctor in charge has to provide a convincing reason why an alternative treatment is chosen. 2) For a patient without a history of major osteoporotic fracture. Measurement of bone mineral density using dual-energy X-ray absorptiometry (DXA), and appropriated treatment described above are provided if osteoporosis is diagnosed based on the result of DXA.	—

Measure

Time frame

The difference in the proportion of the patients who received "appropriate treatments" for osteoporosis between two groups. The definition of "appropriate treatments" is as follows. 1) For a patient with a history of major osteoporotic fracture (either hip or vertebral fracture). Oral bisphosphonate or denosumab in addition to vitamin D supplement . If a patient is not considered to be a good candidate for oral bisphosphonate or denosumab, the doctor in charge has to provide a convincing reason why an alternative treatment is chosen. 2) For a patient without a history of major osteoporotic fracture. Measurement of bone mineral density using dual-energy X-ray absorptiometry (DXA), and appropriated treatment described above are provided if osteoporosis is diagnosed based on the result of DXA.

—

Secondary

Measure	Time frame
The difference in the proportion of providing a reference letter, which includes a detail of treatment plan about osteoporosis, upon discharge from KRH.	—

Countries

Japan

Contacts

Public ContactRyuichi Sada

Kameda medical center Department of General Internal Medicine

sadametal@gmail.com81-4-7092-2211

Outcome results